The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective.
Efficiency
Elastomeric pump
Immune checkpoint inhibitors
Intravenous infusion
Micro costing
Nivolumab
Pembrolizumab
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
09
01
2024
accepted:
08
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Recent studies have underscored the potential of innovative administration methods to mitigate the capacity burden on healthcare systems, without compromising the quality of care. This study assessed and compared the resource utilization and associated costs of two distinct administration modes of immune checkpoint inhibitors: the innovative elastomeric pump and conventional intravenous infusion. This comparison can inform sustainable healthcare practices and healthcare decision-making to optimize treatment efficiency in an era of escalating healthcare demands. In this micro-costing study, data on resource use and time allocation for drug preparation and administration were collected using an observational, non-interventional study design. Data were registered at the oncology daycare unit and hospital pharmacy. Cost categories included drug acquisition, disposable materials, healthcare professional time for drug administration, drug preparation, and patient time spent at the oncology day care unit. Drug administration through the elastomeric pump resulted in substantially lower healthcare costs when compared to conventional infusion, particularly due to reduced labor and chair time. The elastomeric pump reduced the total chair time by 78% and nurse time by 55%. Total average costs (excluding drug costs) were €103,47 and €77.99 for conventional infusion and the elastomeric pump, respectively, showcasing potential savings of €25.48 (P < 0.001) per administration. This study demonstrated that the elastomeric pump not only offers substantial cost savings but also enhances the treatment capacity of the oncology day care unit. These findings support the adoption of the elastomeric pump in clinical settings as a cost-saving and efficient alternative to conventional infusion. This study has been registered in the National Trial Register (NTR), with the reference number NTR NL9473. Registration date: 05-05-2021.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have underscored the potential of innovative administration methods to mitigate the capacity burden on healthcare systems, without compromising the quality of care. This study assessed and compared the resource utilization and associated costs of two distinct administration modes of immune checkpoint inhibitors: the innovative elastomeric pump and conventional intravenous infusion. This comparison can inform sustainable healthcare practices and healthcare decision-making to optimize treatment efficiency in an era of escalating healthcare demands.
METHODS
METHODS
In this micro-costing study, data on resource use and time allocation for drug preparation and administration were collected using an observational, non-interventional study design. Data were registered at the oncology daycare unit and hospital pharmacy. Cost categories included drug acquisition, disposable materials, healthcare professional time for drug administration, drug preparation, and patient time spent at the oncology day care unit.
RESULTS
RESULTS
Drug administration through the elastomeric pump resulted in substantially lower healthcare costs when compared to conventional infusion, particularly due to reduced labor and chair time. The elastomeric pump reduced the total chair time by 78% and nurse time by 55%. Total average costs (excluding drug costs) were €103,47 and €77.99 for conventional infusion and the elastomeric pump, respectively, showcasing potential savings of €25.48 (P < 0.001) per administration.
CONCLUSIONS
CONCLUSIONS
This study demonstrated that the elastomeric pump not only offers substantial cost savings but also enhances the treatment capacity of the oncology day care unit. These findings support the adoption of the elastomeric pump in clinical settings as a cost-saving and efficient alternative to conventional infusion.
TRIAL REGISTRATION
BACKGROUND
This study has been registered in the National Trial Register (NTR), with the reference number NTR NL9473. Registration date: 05-05-2021.
Identifiants
pubmed: 39482711
doi: 10.1186/s12913-024-11719-0
pii: 10.1186/s12913-024-11719-0
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Elastomers
0
Types de publication
Journal Article
Observational Study
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1322Informations de copyright
© 2024. The Author(s).
Références
Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45.
doi: 10.1186/s13045-021-01056-8
pubmed: 33741032
pmcid: 7977302
Challinor JM, Alqudimat MR, Teixeira TOA, Oldenmenger WH. Oncology nursing workforce: challenges, solutions, and future strategies. Lancet Oncol. 2020;21(12):e564–74.
doi: 10.1016/S1470-2045(20)30605-7
pubmed: 33212044
Gourd E. Concern over cancer treatment delays caused by staffing shortages. Lancet Oncol. 2023;24(7):721.
doi: 10.1016/S1470-2045(23)00267-X
pubmed: 37245519
Frosch ZAK, Illenberger N, Mitra N, Boffa DJ, Facktor MA, Nelson H, et al. Trends in patient volume by Hospital Type and the Association of these Trends with Time to Cancer Treatment initiation. JAMA Netw Open. 2021;4(7):e2115675.
doi: 10.1001/jamanetworkopen.2021.15675
pubmed: 34241630
pmcid: 8271360
Tan SS, Van Gils CW, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA. The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health. 2010;13(6):712–9.
doi: 10.1111/j.1524-4733.2010.00740.x
pubmed: 20561330
Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, et al. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anticancer Drugs. 2018;29(8):791–801.
doi: 10.1097/CAD.0000000000000648
pubmed: 29846248
De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med. 2016;5(3):389–97.
doi: 10.1002/cam4.573
pubmed: 26806010
pmcid: 4799946
World Health Organization, Trial Search Portal, Trial ID. NL9473, https://trialsearch.who.int/Trial2.aspx?TrialID=NL9473 . Accessed May 2024.
Sabbagh Dit Hawasli R, Barton S, Nabhani-Gebara S. Ambulatory chemotherapy: past, present, and future. J Oncol Pharm Pract. 2021;27(4):962–73.
doi: 10.1177/1078155220985916
pubmed: 33461412
pmcid: 8193584
Hakkaart-van Roijen L et al. Dutch costing manual: methodology for costing studies and reference prices for economic evaluations in health care [in Dutch: Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg]. 2015. https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg . Accessed May 2024.
Kanters TA, Bouwmans CAM, van der Linden N, Tan SS, Hakkaart-van Roijen L. Update of the Dutch manual for costing studies in health care. PLoS ONE. 2017;12(11):e0187477.
doi: 10.1371/journal.pone.0187477
pubmed: 29121647
pmcid: 5679627
Dutch Central Bureau of Statistics (CBS). Consumer price index. Available via: https://www.cbs.nl/nl-nl/cijfers/detail/83131NED . Accessed May 2024.
Dutch National Healthcare Institute (In Dutch. Zorginstituut Nederland), Medicijnkosten, Available via: https://www.medicijnkosten.nl . Accessed May 2024.
De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella AM, et al. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous infusion: a Time and Motion Study in eight countries. PLoS ONE. 2016;11(6):e0157957.
doi: 10.1371/journal.pone.0157957
pubmed: 27362533
pmcid: 4928781
Mihajlovic J, Bax P, van Breugel E, Blommestein HM, Hoogendoorn M, Hospes W, et al. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous infusion. Clin Ther. 2017;39(6):1221–32. e4.
doi: 10.1016/j.clinthera.2017.05.342
pubmed: 28579210
McCloskey C, Ortega MT, Nair S, Garcia MJ, Manevy F. A systematic review of Time and Resource Use costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a hospital setting. Pharmacoecon Open. 2023;7(1):3–36.
doi: 10.1007/s41669-022-00361-3
pubmed: 35996066
ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT03656718. https://clinicaltrials.gov/ct2/show/NCT03656718 . Accessed May 2024.
ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT03665597. https://clinicaltrials.gov/ct2/show/NCT03665597 . Accessed May 2024.
Malmberg R, Zietse M, Dumoulin DW, Hendrikx J, Aerts J, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23(12):e552–61.
doi: 10.1016/S1470-2045(22)00554-X
pubmed: 36455584
Peer CJ, Zimmerman SM, Figg WD, Goldstein DA, Ratain MJ. Subcutaneous atezolizumab: a Jab without a benefit. Clin Pharmacol Drug Dev. 2022;11(1):134–5.
doi: 10.1002/cpdd.1061
pubmed: 34951144
Lonardi S, Lugowska I, Jackson CGCA, et al. CheckMate 8KX: phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (± rHuPH20). J Clin Oncol. 2021;39:Article2575.
doi: 10.1200/JCO.2021.39.15_suppl.2575
Conrad R, Jacobs BL, Rapoport GL, Cohen M, Lala C, De Miranda, Silva, et al. Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 cohort A in metastatic melanoma. Cancer Res 1 July. 2021;81(13Supplement):CT143.
Franken M, Kanters T, Coenen J, de Jong P, Jager A, Groot CU. Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. Breast. 2020;52:71–7.
doi: 10.1016/j.breast.2020.05.001
pubmed: 32447129
pmcid: 7487951
Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ. 2009;10(1):39–45.
doi: 10.1007/s10198-008-0101-x
pubmed: 18340472
European Medicines Agency. Summary of Product Characteristics Trastuzumab, https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_nl.pdf . Accessed May 2024.